Abstracts tagged "Outcome measures"

Abstract Number: 2497 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³, Ansaam Daoud⁴, Loai Dweik⁵, Hashim Syed⁶ and Omer Pamuk⁷, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁶Case Western/ UH, Cleveland, ⁷University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem. There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
Abstract Number: 0269 • ACR Convergence 2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Yiling Zhang¹, Sara Tedeschi², Abhishek Abhishek³, Owen Hensey⁴, David Grossberg⁵, Ken Cai⁶, Beverley Shea⁷, Jasvinder Singh⁸, Robin Christensen⁹, Teodora Serban¹⁰, Edoardo Cipolletta¹¹, Konstantinos Parperis¹², César Díaz¹³, Geraldine McCarthy¹⁴, Fabio Becce¹⁵, Tamer A Gheita¹⁶, Silvia Sirotti¹⁷, Sara Nysom Christiansen¹⁸, Luis Coronel Tarancon¹⁹, Lisa Stamp²⁰, Yousra H Abdel-Fattah²¹, Tristan Pascart²², Georgios Filippou¹⁷, Lih En Hong²³, John FitzGerald²⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Brigham and Women's Hospital, Boston, MA, ³University of Nottingham, Nottingham, United Kingdom, ⁴OMERACT patient research partner, Dublin, Ireland, ⁵OMERACT patient research partner, Maryland, ⁶Westmead Hospital, Sydney, New South Wales, Australia, ⁷Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁸Baylor College of Medicine, Birmingham, AL, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Ospedale La Colletta, Bucharest, Romania, ¹¹Polytechnic University of Marche, Ancona, Italy, ¹²University of Cyprus Medical School, Nicosia, Cyprus, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁵Lausanne University Hospital (CHUV), Lausanne, Switzerland, ¹⁶Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁷IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ¹⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ¹⁹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ²⁰University of Otago, Christchurch, Christchurch, New Zealand, ²¹Alexandria University, Alexandria, Egypt, ²²Lille Catholic University, Lille, France, ²³Royal Adelaide Hospital, Unley Park, South Australia, Australia, ²⁴UCLA, Los Angeles, CA
Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.Methods:…
Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Sofia Ramiro², Dafne Capelusnik³ and Anna Molto⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Leiden University Medical Center, Bunde, Netherlands, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0857 • ACR Convergence 2024
Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…
Abstract Number: 1180 • ACR Convergence 2024
Relationship Between Changes in Physical Activity and Early Onset Knee Osteoarthritis in Individuals After ACL Reconstruction
David Werner¹, Yvonne Golightly¹, Michael Rosenthal¹, Balasrinivasa Sajja¹, Christopher Wichman¹, Melissa Manzer², Matthew Tao¹ and Elizabeth Wellsandt¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Private Practice, Omaha
Background/Purpose: Low physical activity levels are associated with osteoarthritis (OA) development and progression in individuals at risk for OA development. Including both structural and symptomatic…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 1977 • ACR Convergence 2024
Three-dimensional Stereophotogrammetry Has Utility in Tracking Upper Eyelid Involvement and Overall Disease Worsening in Patients with Craniofacial Localized Scleroderma
Tyler Cepica¹, Jennifer Foster², Priya Sarlashkar², Rami Hallac³ and Heidi Jacobe², ¹University of Texas Southwestern Medical School, Benbrook, TX, ²The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, ³The University of Texas Southwestern Medical Center, Department of Pastic Surgery, Dallas, TX
Background/Purpose: Craniofacial localized scleroderma’s (LoS) indolent and subtle course poses challenges in quantifying disease progression. Traditional serial photography and the Localized Scleroderma Cutaneous Assessment Tool…
Abstract Number: 2246 • ACR Convergence 2024
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
Veena Ranganath¹, Holly Wilhalme², Nicolette Morris³, Jenny Brook², Mihaela Taylor¹, Howard Yang¹, Tanaz Kermani⁴, Thanda Aung², Brian Skaggs¹, David Elashoff⁵ and ziva Cooper⁶, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, ⁴University of California Los Angeles, Santa Monica, CA, ⁵UCLA Department of Medicine Statistics Core, Los Angeles, ⁶UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles
Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
Abstract Number: 2501 • ACR Convergence 2024
Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Rohit Vijjhalwar¹, Vithushanan Ketheeswaranathan², Aman More², Rajinder Andev³ and Shirish Dubey⁴, ¹University of Oxford, Staines, United Kingdom, ²Medical Sciences Division, University of Oxford, Oxford, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom
Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…
Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Kathryn Torok¹, Paulina Horvei¹, Franziska Rosser¹, Kirsten Rose-felker², Vibha Sood², Adam Olsen², Nicole Hogue², Vickie Vandergrift², Lauren Farver², Devin Mcguire², Jonathan Li³, Haley Havrilla², Jessie Alexander⁴, Shawna McIntyre² and Paul Szabolcs¹, ¹University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Stanford Children's Hospital, Palo Alto, CA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0329 • ACR Convergence 2023
Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study
Eike von Schlichting¹, Jan Dieris-Hirche², Imke Redeker³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²LWL-University Hospital, Department of Psychosomatic Medicine and Psychotherapy, Ruhr Universität Bochum, Bochum, Germany, ³Ruhr Universität Bochum, Bochum, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Mental health contributes to the morbidity of patients with inflammatory rheumatic musculoskeletal disease (iRMD). Despite extensive research conducted on the prevalence of depressive disorders,…
Abstract Number: 0619 • ACR Convergence 2023
Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review
liubov Petelytska¹, Francesco Bonomi², Carlo Cannistrà³, elisa Fiorentini⁴, Silvia Peretti³, Sara Torracchi³, Pamela Bernardini³, Carmela Coccia³, Riccardo De Luca³, Alessio Economou³, Juela Levani⁵, marco Matucci Cerinic⁶, Oliver Distler⁷ and Cosimo Bruni⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²University of Florence, Firenze, Italy, ³University of Florence, Florence, Italy, ⁴Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, ⁵Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: There is no established consensus on defining the clinical course and the outcomes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), both among experts and…
Abstract Number: 1140 • ACR Convergence 2023
Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC
Background/Purpose: Patients consult rheumatologists for symptoms which may result from inflammatory activity or reversible problems (INF), joint or other organ damage or irreversible problems (DAM),…

« Previous Page
1
…
8
9
10
11
12
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].